{"id":"NCT00372697","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly","officialTitle":"A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2007-10","completion":"2007-10","firstPosted":"2006-09-07","resultsPosted":"2011-05-17","lastUpdate":"2011-05-17"},"enrollment":28,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acromegaly"],"interventions":[{"type":"DRUG","name":"Octreotide acetate 30 mg suspension","otherNames":["Sandostatin LAR"]}],"arms":[{"label":"Octreotide 30 mg every 21 days","type":"EXPERIMENTAL"},{"label":"Octreotide 60 mg every 28 days","type":"EXPERIMENTAL"}],"summary":"This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.","primaryOutcome":{"measure":"Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24)","timeFrame":"Screening to end of study (Week 24)","effectByArm":[{"arm":"Octreotide 30 mg Every 21 Days","deltaMin":-1.7,"sd":9.9},{"arm":"Octreotide 60 mg Every 28 Days","deltaMin":-2.1,"sd":3.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":["21212103"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Diarrhoea","Flatulence"]}}